IL6 and COVID-19: One clinical trial (https://clinicaltrials.gov/ct2/show/ChiCTR2000029765), using the IL-6 receptor-targeted monoclonal antibody tocilizumab (TCZ), which blocks IL-6-mediated signals by inhibiting IL-6 binding to transmembrane and soluble IL-6 receptors, reported quick control of fever and an improvement of respiratory function in 21 patients with severe COVID-19 treated in Anhui, China [6].